Participated · Series A · May 2026

Latus Bio develops a gene therapy platform that pairs proprietary and engineered AAV capsids with clinically optimized routes of administration to enable efficient delivery at low doses. The company’s two lead programs are LTS-101 for CLN2 disease, which has IND clearance and multiple FDA designations, and LTS-201 for Huntington’s disease, which is being prepared for IND submission. Latus is advancing capsid variants for potential application beyond CNS disorders, including kidney, eye, heart, and muscle diseases. Management emphasizes scalability and lower-dose delivery to improve safety, manufacturability, and cost, targeting larger rare and broader CNS indications. The company raised $97 million in its Series A (including a $43 million extension) to fund operations through key clinical milestones for these programs.

Participated · Seed · Nov 2025

Ladder Bio (formerly ThirdLaw Molecular) is a therapeutics company pioneering a proprietary Spiroligomer platform that engineers sequence-defined, structurally preorganized “ladder-shaped” peptide-like molecules. These molecules aim to drug historically undruggable targets by marrying biologics-like affinity and selectivity with small-molecule properties such as oral dosing and cell permeability. The company’s initial focus is on platform scale-up, lead program validation, and in-vitro screening to advance its first drug candidates. Proceeds from its recent seed financing will also fund key hires across chemistry, biology, and development. Ladder Bio plans to translate its platform into high-value medicines and expand its capabilities as it moves from platform validation toward product development. Industry veteran Eric Heil has been appointed CEO, and noted life-science investors David Scheer and Brian Halak have joined the board, strengthening operational and strategic oversight. Headquartered in Blue Bell, Pennsylvania, the company positions itself to become a category-leading player in next-generation peptide therapeutics. To date, Ladder Bio has raised $5.5 million in seed capital, providing its current financial runway.

Participated · Equity · Nov 2024

Vittoria Biotherapeutics is a clinical-stage immunotherapy company developing novel cell therapies for hard-to-treat diseases. Its lead program, VIPER-101, is a gene-edited, autologous dual-population T cell therapy designed to target CD5 for patients with T-cell lymphoma. VIPER-101 and other assets leverage the company’s proprietary Senza5 platform, which enhances T cell effector function by abrogating CD5-mediated immunosuppression and employs a rapid five-day manufacturing process. Senza5 has demonstrated outstanding preclinical anti-tumor efficacy across a range of liquid and solid tumor models, and the broader pipeline includes programs targeting solid tumors and autoimmune diseases. The company recently completed a $25 million private financing to support clinical proof-of-concept for VIPER-101. The VIPER-101 Phase 1 trial is actively recruiting patients (ClinicalTrials.gov NCT06420089). The technology is exclusively licensed from the University of Pennsylvania, which also holds equity and has existing financial relationships with Vittoria.